Table 2.
The individual and sequential impact of each eligibility criterion according to VICTORIA in KorAHF registry population with complete information for eligibility assessment
| VICTORIA criteria | Prevalence | |
|---|---|---|
| Individually (%) | Sequentially (%) | |
| 1. Age ≥18 years | 100% | |
| 2. LVEF ≤ 45% | 100% | |
| 3. Prior HF hospitalization within 6 months | 100% | |
| 4. SBP ≥ 100 mmHg | 78.1% | 78.1% |
| 5. Elevated natriuretic peptide a | 79.9% | 62.2% |
| 6. eGFR ≥ 15 mL/min/1.73 m2 | 94.9% | 58.0% |
| 7. eGFR ≥ 30 mL/min/1.73 m2 | 88.2% | 52.5% |
BNP, B‐type natriuretic peptide; eGFR, estimated glomerular filtration rate; HF, heart failure; KorAHF, Korean Acute Heart Failure registry; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; SBP, systolic blood pressure; VICTORIA, Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction.
a
BNP ≥ 300 pg/mL or NT‐proBNP ≥ 1000 pg/mL for sinus rhythm and BNP ≥ 500 pg/mL or NT‐proBNP ≥ 1600 pg/mL for atrial fibrillation.